TruSight Oncology Family Grows with Liquid Biopsy and High-Throughput Assay Additions
April 24, 2020
Providing customers with a versatile, scalable, sample-to-report workflow
Craigavon, U.K., 24 April 2020 – Bringing comprehensive genomic profiling (CGP) one step closer to the standard of care in oncology, Illumina is now shipping TruSight™ Oncology 500 ctDNA (TSO 500 ctDNA), our first liquid biopsy solution for detecting cancer biomarkers, and TruSight Oncology 500 High-Throughput (TSO 500 HT), enabling high-throughput implementation by large labs with high-volume tissue sample needs. TSO 500 ctDNA and TSO 500 HT provide labs with the flexibility to run tissue or blood plasma samples on a single high-throughput platform, the NovaSeq™ 6000 Sequencing System. These two new additions join the TruSight Oncology 500 (TSO 500) family – the tissue-based version of the assay, which is optimized for both the NextSeq 550 and NextSeq 550Dx Systems. TruSight Oncology 500 products are currently intended for research use only (RUO).
TSO 500 ctDNA enables non-invasive, comprehensive genomic profiling of circulating tumor DNA (ctDNA) when tissue testing is not optimal, or to complement tissue-based testing. TSO 500 ctDNA is one of the first liquid biopsy assays to enable comprehensive genomic profiling that interrogates the sequence of 523 genes in key cancer-related pathways, including single-nucleotide variants (SNVs), Indels, copy-number variants (CNVs), fusions, microsatellite instability (MSI) and tumor mutational burden (TMB).
Optimized for the NovaSeq 6000, TSO 500 ctDNA offers both the economic value and the scale of sequencing needed to properly interrogate ctDNA at high levels of sensitivity and specificity. Complementing TSO 500 ctDNA on the NovaSeq 6000 is TSO 500 HT, providing large labs the ability to perform CGP analysis of up to 192 FFPE samples at a time, in a single NovaSeq sequencing run. Additionally, the two assays offer comprehensive coverage including a majority of the known and anticipated biomarkers associated with guidelines and clinical trials.
“We believe in the advancement of personalized medicine guided by molecular-based testing to improve patient outcomes,” said Margot P. Schoenborn, CEO of OmniSeq, Inc. “TSO 500 HT gives us the scalability to process a large number of samples every week, in that we can batch from 16 to 192 samples in a single run on the NovaSeq. Having the flexibility to run multiple flow cell options will enable us to optimize sequencing runs based on clinical volumes and flexibility to meet the turnaround time requirements of our customers.”
By offering solutions that independently interrogate both tissue and liquid biopsies on the NovaSeq 6000, Illumina’s TSO 500 portfolio enables a complete solution of in-house quality comprehensive genomic profiling assays, providing customers with:
- Flexibility and efficiency to deploy the same oncology panel, on the same sequencing platform, regardless of sample type
- Ability to run comparability of results in tissue and blood from a single individual, or across individuals
- Scalability to meet high-throughput lab requirements
“Comprehensive genomic profiling on the DNA- and RNA- level will play an increasing role for cancer precision medicine,” said Professor Albrecht Stenzinger, MD, from the Institute of Pathology at University Hospital in Heidelberg, Germany. “There is a growing number of drug targets, as well as an emerging landscape of resistance mechanisms, that will make large panels, which I define as panels with more than 1 Megabase genomic footprint, not the exception, but the norm. High quality data with low TAT will be crucial in this context,” he concluded.
Offering an impressive sample-to-answer workflow, with a five-day turn-around time
Secondary analysis of large liquid biopsy CGP panels can be challenging. To address this issue, TSO 500 ctDNA utilizes the Illumina DRAGENTM (Dynamic Read Analysis for GENomics) Bio-IT Platform to provide accurate and ultra-rapid secondary analysis of sequencing data. TSO 500 ctDNA leverages the combination of the DRAGEN Bio-IT server hardware and DRAGEN TruSight Oncology 500 ctDNA Analysis Software to offer an accelerated, easy-to-implement, fully integrated set of bioinformatics algorithms to overcome ctDNA challenges, and ensure optimal assay performance. This is important because it provides robust and accelerated comprehensive variant calling, at very low limits of detection, in a single solution.
Dr. Steven Walker, Head of Product Development, Almac Diagnostic Services said: “This innovate product from Illumina will enable Almac to provide Pharmaceutical and Biotech companies with a new liquid biopsy option to support their translational research, clinical trials and CDx development. The assay, based on the TSO 500 platform, allows the mutational assessment of 523 genes from a single liquid biopsy sample. Integration of the Illumina DRAGEN™ Bio-IT platform into the workflow will help to significantly reduce the turnaround time for complex data analysis for our clients.
He continued: “Almac sees this product as a key component in our broad range of biomarker solutions. From the pharma or biotech perspective, this platform will enable biomarker discovery and testing from non-invasive samples, rather than typical tumor biopsy based methods which can be challenging. We believe this large panel and powerful analysis platform will enable our clients to effectively develop exciting new biomarkers for novel therapeutics.”
The TSO 500 menu, including TSO 500, TSO 500 ctDNA [WL1] and TSO 500 HT offer Pierian Dx’s streamlined tertiary interpretation and reporting, from their Clinical Genomics Workspace (CGW) platform. Powered by a comprehensive Clinical Genomics Knowledgebase, CGW gives customers the ability to identify and categorize pathogenic variants, and build a final annotated interpretation report. The combination of Illumina’s comprehensive tumor profiling assays coupled with DRAGEN and PierianDx’s variant interpretation and reporting solutions provides customers with a seamless and semi-automated workflow, from sample to final report.
Read Chief Medical Officer, Phil Febbo’s, perspective on the power and promise of liquid biopsies here. For more information on TSO 500 ctDNA and TSO 500 High-Throughput, click here.
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia.
To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacbrand.beingbuilt.uk.